Skip to main content

Table 1 Comparison between the screened and the final study cohort

From: Association between serum IgG level and clinical course in primary sclerosing cholangitis

  Final study cohort N = 148 Screened cohort N = 446 p-value
Gender [Male %f] 105 (70.9%) 312 (70.0%) P = 0.82
Median age at initial diagnose [in years] 33.5 (26–47) 32 (24–44) P = 0.21
Median time of follow-up [in years] 9 (3–14) 9 (4–14) P = 0.91
Patients diagnosed with AIH/PSC overlap 9 (6.1%) 29 (6.6%) P = 0.82
Presence of dominant stenosis 87 (58.8%) 268 (60.6%) P = 0.72
Presence of IBD 99 (66.9%) 315 (70.9%) P = 0.42
BMI 22.7 (17.1–31.9) 22.7 (17.3–56.7) P = 0.5
Mayo Risk Score (MRS) −0.2 (−3.1–2.3) −0.1 (− 2.7–2.8) P = 0.8
OLT 32 (21.6%) 107 (30.4%) P = 0.042
Re-OLT 9 (6.1%) 21 (6%) P = 1.02
Death 37 (25%) 66 (18.8%) P = 0.22
Combined end-point (OLT and death) 57 (38.5%) 144 (40.9%) P = 0.62
CCA 12 (8.1%) 31 (8.8%) P = 0.82
  1. 1Mann-Witney- U test was applied
  2. 2Chi2-Test was applied
  3. Abbreviation: AIH/PSC = autoimmune hepatitis/primary sclerosing cholangitis, CCA = cholangiocarcinoma, IBD = Inflammatory bowel disease, MRS = Mayo Risk ScoreOLT = orthotopic liver transplantation